$16.73
3.98% yesterday
Nasdaq, Nov 25, 10:01 pm CET
ISIN
US87164F1057
Symbol
SNDX
Sector
Industry

Syndax Pharmaceuticals Inc Stock price

$16.73
-2.02 10.77% 1M
-3.55 17.50% 6M
-4.88 22.58% YTD
+1.25 8.07% 1Y
-0.10 0.59% 3Y
+9.51 131.72% 5Y
+4.72 39.30% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.64 3.98%
ISIN
US87164F1057
Symbol
SNDX
Sector
Industry

Key metrics

Market capitalization $1.43b
Enterprise Value $1.04b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 64.95
P/S ratio (TTM) P/S ratio 89.25
P/B ratio (TTM) P/B ratio 3.91
Revenue (TTM) Revenue $16.00m
EBIT (operating result TTM) EBIT $-321.21m
Free Cash Flow (TTM) Free Cash Flow $-258.86m
Cash position $389.61m
EPS (TTM) EPS $-3.63
P/E forward negative
P/S forward 37.85
EV/Sales forward 27.55
Short interest 12.60%
Show more

Is Syndax Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Syndax Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Syndax Pharmaceuticals Inc forecast:

14x Buy
93%
1x Hold
7%

Analyst Opinions

15 Analysts have issued a Syndax Pharmaceuticals Inc forecast:

Buy
93%
Hold
7%

Financial data from Syndax Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
16 16
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 106 106
96% 96%
662%
- Research and Development Expense 231 231
66% 66%
1,445%
-321 -321
66% 66%
-2,008%
- Depreciation and Amortization 0.01 0.01
97% 97%
0%
EBIT (Operating Income) EBIT -321 -321
66% 66%
-2,008%
Net Profit -297 -297
69% 69%
-1,857%

In millions USD.

Don't miss a Thing! We will send you all news about Syndax Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Syndax Pharmaceuticals Inc Stock News

Positive
Reuters
11 days ago
The U.S. Food and Drug Administration on Friday approved Syndax Pharmaceuticals' drug for the treatment of adult and pediatric patients with a type of blood cancer, sending the company's shares up 3% in after-hours trading.
Neutral
PRNewsWire
11 days ago
– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation – – Syndax to host conference call today at 6:00 p.m. ET – WALTHAM, Mass.
Positive
Seeking Alpha
14 days ago
Primary endpoint of pivotal phase 2 study met with statistical significance in using Revumenib for the treatment of relapsed/refractory mNPM1 AML patients; sNDA expected 1st half 2025. PDUFA action date of December 26th of 2024 deployed for FDA to decide if Revumenib should be approved for the treatment of relapsed/refractory KMT2Ar Acute leukemia patients. The global acute myeloid leukemia mar...
More Syndax Pharmaceuticals Inc News

Company Profile

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include candidate and entinostat. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

Head office United States
CEO Michael Metzger
Employees 184
Founded 2005
Website www.syndax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today